Showing results (31-40 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 TrialsJean-Luc Harousseau, Herve Avet-Loiseau, Michel Attal, et al.
Blood|March 19, 2015
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myelomaPhilippe Moreau, Brigitte Kolb, Michel Attal, et al.
Rheumatology (Oxford, England)|August 4, 2023
Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registryDéborah Faganello, Anne Bertrand, Pauline Meunier, et al.
Blood|January 7, 2006
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myelomaFrederic Garban, Michel Attal, Mauricette Michallet, et al.
Leukemia & Lymphoma|February 25, 2020
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myelomaMurielle Roussel, Benjamin Hebraud, Cyrille Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trialJean-Luc Harousseau, Michel Attal, Hervé Avet-Loiseau, et al.
Haematologica|December 3, 2011
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trialMartin Kropff, Honorata Giongco Baylon, Jens Hillengass, et al.
British Journal of Haematology|May 26, 2021
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogeneticsSimon J Harrison, Aurore Perrot, Adrian Alegre, et al.
Blood|June 15, 2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trialsPeter M Fayers, Antonio Palumbo, Cyrille Hulin, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2025
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort StudyAlexis Talbot, Cyrille Hulin, Aurore Perrot, et al.
Pageof 15